Regulus Therapeutics Inc. [NASDAQ: RGLS] closed the trading session at $0.93 on 06/15/21. The day’s price range saw the stock hit a low of $0.92, while the highest price level was $0.9999. The company report on May 21, 2021 that Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program.
Data to Be Presented at the Oppenheimer Rare & Orphan Disease Summit.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), announced an incremental update from the first cohort of patients with ADPKD in its ongoing Phase 1b clinical trial of RGLS4326. The study is evaluating the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326 in patients with ADPKD.
The stocks have a year to date performance of -30.98 percent and weekly performance of -23.62 percent. The stock has been moved at -16.05 percent over the last six months. The stock has performed 5.89 percent around the most recent 30 days and changed -46.45 percent over the most recent 3-months.
If compared to the average trading volume of 2.81M shares, RGLS reached to a volume of 5918392 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Regulus Therapeutics Inc. [RGLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RGLS shares is $1.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RGLS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR Inc. have made an estimate for Regulus Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2018. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on January 05, 2018, representing the official price target for Regulus Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Chardan Capital Markets kept a Buy rating on RGLS stock. On March 06, 2017, analysts decreased their price target for RGLS shares from 8 to 6.
The Average True Range (ATR) for Regulus Therapeutics Inc. is set at 0.11, with the Price to Sales ratio for RGLS stock in the period of the last 12 months amounting to 7.05. The Price to Book ratio for the last quarter was 2.45, with the Price to Cash per share for the same quarter was set at 0.42.
RGLS stock trade performance evaluation
Regulus Therapeutics Inc. [RGLS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.62. With this latest performance, RGLS shares gained by 5.89% in over the last four-week period, additionally sinking by -16.05% over the last 6 months – not to mention a drop of -0.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RGLS stock in for the last two-week period is set at 40.47, with the RSI for the last a single of trading hit 36.60, and the three-weeks RSI is set at 42.13 for Regulus Therapeutics Inc. [RGLS]. The present Moving Average for the last 50 days of trading for this stock 1.1434, while it was recorded at 1.0539 for the last single week of trading, and 1.0472 for the last 200 days.
Regulus Therapeutics Inc. [RGLS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Regulus Therapeutics Inc. [RGLS] shares currently have an operating margin of -141.47. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -157.21.
Return on Total Capital for RGLS is now -42.58, given the latest momentum, and Return on Invested Capital for the company is -68.25. Return on Equity for this stock declined to -68.33, with Return on Assets sitting at -39.48. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 19.69. Additionally, RGLS Total Debt to Total Capital is recorded at 16.45, with Total Debt to Total Assets ending up at 13.63.
Reflecting on the efficiency of the workforce at the company, Regulus Therapeutics Inc. [RGLS] managed to generate an average of -$655,417 per employee. Receivables Turnover for the company is 12.17 with a Total Asset Turnover recorded at a value of 0.25.Regulus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 3.70.
Earnings per share (EPS) analysis for Regulus Therapeutics Inc. [RGLS] stock
With the latest financial reports released by the company, Regulus Therapeutics Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -109.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc. go to 39.60%.
Regulus Therapeutics Inc. [RGLS]: Insider Ownership positions
There are presently around $25 million, or 49.70% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 6,451,056, which is approximately 0% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 3,220,758 shares of the stock with an approximate value of $3.0 million in RGLS stocks shares; and POINT72 ASSET MANAGEMENT, L.P., currently with $3.0 million in RGLS stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Regulus Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 30 institutional holders increased their position in Regulus Therapeutics Inc. [NASDAQ:RGLS] by around 14,489,112 shares. Additionally, 12 investors decreased positions by around 5,613,571 shares, while 8 investors held positions by with 7,185,964 shares. The mentioned changes placed institutional holdings at 27,288,647 shares, according to the latest SEC report filing. RGLS stock had 20 new institutional investments in for a total of 8,172,618 shares, while 7 institutional investors sold positions of 5,451,036 shares during the same period.